Histidine-rich glycoprotein
AssigneeInnoventus Project AB
InventorsAnna-Karin Olsson, Helena Larsson, Lena Claesson-Welsh
Life of this patent
Estimating the term…
Abstract
The invention relates to histidine-rich glycoprotein (HRGP) polypeptides and the use of these polypeptides. The invention includes methods for the inhibition of angiogenesis by administering an HRGP polypeptide. The invention also includes pharmaceutical compositions and articles of manufacture comprising HRGP polypeptides, antibodies and receptors that bind to an HRGP polypeptide, HRGP-depleted plasma and polynucleotides, vectors and host cells that encode HRGP polypeptides.
Claims50
A composition comprising a substantially pure histidine-rich glycoprotein polypeptide and an anti-angiogenic agent.
A composition comprising a substantially pure histidine-rich glycoprotein polypeptide and an anti-neoplastic agent.
An article of manufacture comprising packaging material and a substantially pure histidine-rich glycoprotein polypeptide within said packaging material, wherein said packaging material comprises a label or package insert indicating said polypeptide is to be administered to a mammal for the inhibition of angiogenesis.
A method for inhibiting angiogenesis in a mammal, comprising administering a composition comprising a substantially pure histidine-rich glycoprotein polypeptide to said mammal, wherein angiogenesis is inhibited in said mammal.
A method for identifying an anti-angiogenic polypeptide, comprising:
- measuring the effect of an HRGP polypeptide upon FGF-2 induced migration of primary bovine adrenal cortex capillary endothelial cells;
- and
- identifying said HRGP polypeptide as an anti-angiogenic polypeptide when said FGF-2 induced migration is significantly decreased in the presence of said HRGP polypeptide.
A method for identifying an anti-angiogenic polypeptide, comprising:
- measuring the effect of an HRGP polypeptide upon chick chorioallantoic membrane angiogenesis;
- and
- identifying said HRGP polypeptide as an anti-angiogenic polypeptide when said chick chorioallantoic membrane angiogenesis is significantly decreased in the presence of said HRGP polypeptide.
A method for identifying an anti-angiogenic polypeptide, comprising:
- measuring the effect of an HRGP polypeptide upon growth of an angiogenesis-dependent tumor;
- and
- identifying said HRGP polypeptide as an anti-angiogenic polypeptide when said tumor growth is significantly decreased in the presence of said HRGP polypeptide.
An antibody that binds to a histidine-rich glycoprotein polypeptide.
A method of birth control, comprising administering a substantially pure histidine-rich glycoprotein polypeptide to a female mammal.
A method of imaging neovascularization in a mammal, comprising;
- administering a substantially pure histidine-rich glycoprotein polypeptide coupled to a detectable marker to said mammal;
- measuring neovascularization in said mammal based on said detectable marker.
A substantially pure histidine-rich glycoprotein polypeptide coupled to a detectable marker.
A substantially pure histidine-rich glycoprotein polypeptide coupled to a toxin.
A substantially pure receptor that binds to a histidine-rich glycoprotein polypeptide.
Plasma depleted of histidine-rich glycoprotein.
An isolated polynucleotide encoding an HRGP polypeptide fragment.
Dependencies are inferred from the claim text.